Results 21 to 30 of about 13,218 (206)

Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women [PDF]

, 2015
Contains fulltext : 153646.pdf (Publisher’s version ) (Open Access)OBJECTIVES: To describe the pharmacokinetics of darunavir in pregnant HIV-infected women in the third trimester and post-partum.
Hawkins, D., Weizsacker, K., Ende, M. van der, Taylor, G., Molto, J., Gingelmaier, A., Sadiq, S.T., Colbers, A., Burger, D.M., Warris, A., Ivanovic, J., Kabeya, K., Giaquinto, C., Ven, A.J.A.M. van der, et al.   +14 more
core   +2 more sources

The Effect of Solvents and Drying Temperature on the Physicochemical Properties of Darunavir and Darunavir Ethanolate Substances

Разработка и регистрация лекарственных средств, 2021
Introduction. Usage of aggressive conditions (solvents, high temperature, etc.) in a dosage form manufacturing can lead to a change in the properties of a pharmaceutical substance.
S. A. Zolotov, I. A. Dain, N. B. Demina, A. S. Zolotova, E. S. Ponomarev   +4 more
doaj   +1 more source

Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART. [PDF]

HIV Med
Abstract Background Data on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual‐ or triple‐antiretroviral therapy (ART) are sparse. Methods Plasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL‐6) were measured at baseline ...
Henderson M, Dutey-Magni P, Herrera C, Stöhr W, Arenas-Pinto A, Swann O, Heslegrave A, Zetterberg H, Tregoning J, Fidler S, Raffi F, Calcagno A, Babiker A, Winston A.   +13 more
europepmc   +2 more sources

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial

AIDS Research and Treatment, 2012
Objectives. Evaluation of pharmacokinetics and pharmacodynamics of darunavir and etravirine among HIV-1–infected, treatment-experienced adults from GRACE, by sex and race. Methods.
Thomas Kakuda, Vanitha Sekar, Peter Vis, Bruce Coate, Robert Ryan, David Anderson, Guy De La Rosa, Joseph Mrus   +7 more
doaj   +1 more source

Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States

AIDS Research and Therapy, 2021
Introduction Although individual antiretroviral drugs have been shown to be associated with elevated cardiovascular disease (CVD) risk, data are limited on the role of antiretroviral drug combinations.
Kunchok Dorjee, Manisha Desai, Tsering Choden, Sanjiv M. Baxi, Alan E. Hubbard, Arthur L. Reingold   +5 more
doaj   +1 more source

Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study

Current Issues in Molecular Biology, 2022
Candida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has ...
Juliana de C. Fenley, Patrícia P. de Barros, Paulo H. F. do Carmo, Maíra T. Garcia, Rodnei D. Rossoni, Juliana C. Junqueira   +5 more
doaj   +1 more source

Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro [PDF]

Antimicrobial Agents and Chemotherapy, 2017
ABSTRACT Treatment of HIV-infected patients coinfected with Mycobacterium tuberculosis is challenging due to drug-drug interactions (DDIs) between antiretrovirals (ARVs) and antituberculosis (anti-TB) drugs.
Roberts, Owain, Khoo, Saye, Owen, Andrew, Siccardi, Marco   +3 more
openaire   +2 more sources

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK [PDF]

, 2016
\ua9 The Author 2016. Background: Darunavir is considered to have a high genetic barrier to resistance. Most darunavir-associated drug resistance mutations (DRMs) have been identified through correlation of baseline genotype with virological response in ...
Clay S, Pillay D, Williams I, Zhang H, Babiker A, Mbisa JL, Clark D, Ramzan F, Kemble C, Douthwaite S, Tilbury S, Hunter M, Taylor C, Bradley-Stewart A, Lynch J, Ainsworth J, Faleye A, Ibrahim F, Hue S, Mbisa T, Booth C, Munshi S, Post F, Fisher M, Kegg S, Sachikonye M, Tostevin A, Kaye S, Lampe F, Gravely J, Miller S, Geretti AM, Shepherd J, Kirk S, Leigh-Brown A, Hopkins M, Hutchinson S, Pritchard J, White E, Russell-Sharpe S, Pozniak A, O'Shea S, Thornton A, Mitchell S, Nastouli E, Cox A, de Souza C, Aitken C, Hubb J, Gilson R, Wilson A, Jose S, Wood C, Sabin CA, Huntington S, Phillips AN, Orkin C, Everett R, Cane P, Delpech V, Sabin C, Chaloner C, Asboe D, Hill T, Winston A, Harte A, Chadwick D, Greatorex J, Gompels M, Fraser C, Ashton L, Glabay A, Hay P, Hale A, Tsintas R, Mackie N, Churchill D, Lazarus L, Hand J, El Bouzidi K, Tilston P, Schmid ML, Carder M, Nelson M, Memon K, Spencer H, Mullen J, Jones R, Mandalia S, Allan S, Youssef E, Johnson M, Lewszuk A, Tandy R, Tariq A, Atkinson C, Leen C, Templeton K, Gunson R, Dunn DT, Fawcett T, Morris S, Fearnhill E, Gleisner Z, Dhillon M, Smit E, Baillie K, Brima N, Smith C, Collins S, Weber J, Walsh J, Fairbrother K, Campbell L, Kellam P, Anderson J, Youle M, Payne B, Porter K, Garcia-Diaz A, Cumming S, Palfreeman A, Pozniak AL, Perry N, Gazzard B, Schwenk A, Adefisan A, Moses S   +127 more
core   +7 more sources

Pharmacological aspects of darunavir/cobicistat [PDF]

, 2016
Rezolsta® (darunavir/cobicistat) es el primer inhibidor de la proteasa potenciado en combinación fija con un nuevo potenciador farmacológico. Darunavir es actualmente el inhibidor de la proteasa de uso preferente con un perfil de eficacia y seguridad ...
Santos-González, Jesús Leandro, González-Doménech, Carmen María, Palacios-Muñoz, María Rosario   +2 more
core   +1 more source

Risk factors contributing to a low darunavir plasma concentration [PDF]

, 2017
Darunavir is an efficacious drug; however, pharmacokinetic variability has been reported. The objective of this study was to find predisposing factors for low darunavir plasma concentrations in patients starting the once- or twice-daily dosage. Darunavir
Touw, Daan J.; id_orcid, Ymkje Stienstra, Touw, Daan J., Alffenaar, Jan Willem C., Jos G. W. Kosterink, Daan J. Touw, Wouter F. W. Bierman, Kosterink, Jos G.W., Kosterink, Jos G.W.; id_orcid, Bierman, Wouter F.W., Jan-Willem C. Alffenaar, Daskapan, Alper, Stienstra, Ymkje, van der Werf, Tjip S., Alper Daskapan, Tjip S. van der Werf   +15 more
core   +2 more sources